Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The company's Targeted Glues are prospectively and rationally designed medicines that have shown promising results in degrading BRD9 via a novel mechanism with DCAF16 E3 ligase.
Author's summary: Amphista Therapeutics publishes breakthrough study on cancer target degradation.
More News
- Time for Action: Investing in Health Canada to Accelerate Access to…
- Islamic Heritage Month event in Cornwall showcases how to build community
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Hugo Rodrigues: A nine-member Cornwall city council? That's disappointing
- MCU: Jeremy Allen White Responds to Popular X-Men Fan Casting
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow